Haemonetics Co. (NYSE:HAE - Free Report) - Zacks Research increased their Q4 2026 earnings estimates for shares of Haemonetics in a note issued to investors on Monday, December 9th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings per share of $1.40 for the quarter, up from their previous estimate of $1.39. The consensus estimate for Haemonetics' current full-year earnings is $4.59 per share. Zacks Research also issued estimates for Haemonetics' FY2027 earnings at $5.92 EPS.
Haemonetics (NYSE:HAE - Get Free Report) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping analysts' consensus estimates of $1.09 by $0.03. The firm had revenue of $345.50 million during the quarter, compared to analyst estimates of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The company's revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.99 EPS.
HAE has been the subject of several other research reports. JPMorgan Chase & Co. began coverage on shares of Haemonetics in a report on Friday, December 6th. They set an "overweight" rating and a $116.00 target price for the company. CL King started coverage on Haemonetics in a report on Friday, September 13th. They issued a "buy" rating and a $116.00 price objective for the company. BTIG Research began coverage on Haemonetics in a research report on Tuesday, September 10th. They issued a "buy" rating and a $112.00 target price on the stock. Needham & Company LLC reissued a "buy" rating and set a $112.00 price target on shares of Haemonetics in a research report on Tuesday, December 3rd. Finally, Bank of America initiated coverage on Haemonetics in a research report on Wednesday, September 11th. They set a "neutral" rating and a $85.00 price target on the stock. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Haemonetics presently has a consensus rating of "Moderate Buy" and an average price target of $108.78.
View Our Latest Analysis on Haemonetics
Haemonetics Stock Down 1.2 %
NYSE:HAE traded down $1.04 during trading hours on Thursday, reaching $82.30. 375,149 shares of the stock were exchanged, compared to its average volume of 552,832. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.49 and a quick ratio of 2.09. Haemonetics has a twelve month low of $70.25 and a twelve month high of $97.97. The stock has a market cap of $4.13 billion, a PE ratio of 34.17, a PEG ratio of 1.26 and a beta of 0.38. The firm has a 50 day moving average of $80.91 and a 200 day moving average of $81.63.
Institutional Investors Weigh In On Haemonetics
Several hedge funds have recently added to or reduced their stakes in the business. Commonwealth Equity Services LLC boosted its holdings in shares of Haemonetics by 3.3% during the second quarter. Commonwealth Equity Services LLC now owns 3,673 shares of the medical instruments supplier's stock worth $304,000 after acquiring an additional 117 shares during the period. Vontobel Holding Ltd. grew its holdings in Haemonetics by 3.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 4,878 shares of the medical instruments supplier's stock valued at $392,000 after buying an additional 180 shares in the last quarter. QRG Capital Management Inc. increased its position in Haemonetics by 6.9% during the 2nd quarter. QRG Capital Management Inc. now owns 4,031 shares of the medical instruments supplier's stock worth $333,000 after buying an additional 260 shares during the period. Arizona State Retirement System lifted its holdings in shares of Haemonetics by 2.0% during the second quarter. Arizona State Retirement System now owns 14,217 shares of the medical instruments supplier's stock worth $1,176,000 after buying an additional 272 shares in the last quarter. Finally, Keene & Associates Inc. boosted its position in shares of Haemonetics by 3.0% in the third quarter. Keene & Associates Inc. now owns 10,174 shares of the medical instruments supplier's stock valued at $818,000 after acquiring an additional 298 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.
Haemonetics Company Profile
(
Get Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
Recommended Stories
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
